Natarajan Sethuraman - Jul 12, 2024 Form 4 Insider Report for Entrada Therapeutics, Inc. (TRDA)

Role
Chief Scientific Officer
Signature
/s/ Jared Cohen, as Attorney-in-Fact
Stock symbol
TRDA
Transactions as of
Jul 12, 2024
Transactions value $
-$22,284
Form type
4
Date filed
7/16/2024, 04:43 PM
Previous filing
May 20, 2024
Next filing
Sep 5, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TRDA Common Stock Sale -$10.8K -600 -0.32% $18.00 189K Jul 12, 2024 Direct F1
transaction TRDA Common Stock Sale -$11.5K -638 -0.34% $18.00 189K Jul 15, 2024 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 14, 2023.